تقرير
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
| العنوان: | Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. |
|---|---|
| المؤلفون: | Locke, Frederick L, Siddiqi, Tanya, Jacobson, Caron A, Ghobadi, Armin, Ahmed, Sairah, Miklos, David B, Perales, Miguel-Angel, Munoz, Javier, Fingrut, Warren B, Pennisi, Martina, Gauthier, Jordan, Shadman, Mazyar, Gowda, Lohith, Mirza, Abu-Sayeef, Abid, Muhammad Bilal, Hong, Sanghee, Majhail, Navneet S, Kharfan-Dabaja, Mohamed A, Khurana, Arushi, Badar, Talha, Lin, Yi, Bennani, N Nora, Herr, Megan M, Hu, Zhen-Huan, Wang, Hai-Lin, Baer, Anjani, Baro, Elande, Miao, Harry, Spooner, Clare, Xu, Hairong, Pasquini, Marcelo C |
| المصدر: | Blood ; ISSN:1528-0020 ; Volume:143 ; Issue:26 |
| بيانات النشر: | Silverchair Information Systems |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients who received axi-cel between 2017 and 2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 trials, respectively. Overall survival was consistent across race/ethnicity groups. However, non-Hispanic (NH) Black patients had lower overall response rate (OR, 0.37; 95% CI, 0.22-0.63) and lower complete response rate (OR, 0.57; 95% CI, 0.33-0.97) than NH White patients. NH Black patients also had a shorter progression-free survival vs NH White (HR, 1.41; 95% CI, 1.04-1.90) and NH Asian patients (HR, 1.67; 95% CI, 1.08-2.59). NH Asian patients had a longer duration of response than NH White (HR, 0.56; 95% CI, 0.33-0.94) and Hispanic patients (HR, 0.54; 95% CI, 0.30-0.97). There was no difference in cytokine release syndrome by race/ethnicity; however, higher rates of any-grade immune effector cell-associated neurotoxicity syndrome were observed in NH White patients than in other patients. These results provide important context when treating patients with R/R LBCL with CAR T-cell therapy across different racial and ethnic groups. ZUMA-1 and ZUMA-7 (ClinicalTrials.gov identifiers: #NCT02348216 and #NCT03391466, respectively) are registered on ClinicalTrials.gov. |
| نوع الوثيقة: | report article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1182/blood.2023023447Test; https://pubmed.ncbi.nlm.nih.gov/38635762Test |
| DOI: | 10.1182/blood.2023023447 |
| الإتاحة: | https://doi.org/10.1182/blood.2023023447Test https://pubmed.ncbi.nlm.nih.gov/38635762Test |
| حقوق: | © 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| رقم الانضمام: | edsbas.E74D9D50 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/blood.2023023447 |
|---|